On April 28, 2025 Attivare Therapeutics, Inc., an innovative oncology company focused on the development of its ATTimmune biomaterial scaffold cancer therapies to treat patients across a range of solid and liquid tumors with significant unmet medical needs, reported it will present preclinical data for its novel ATT-01 and ATT-02 therapeutics in two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025 (Press release, Attivare Therapeutics, APR 28, 2025, View Source [SID1234652290]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ATT-01 uses its ATTimmune platform technology, a silica-based, biodegradable scaffold (mesoporous silica rod, MSR), loaded with GM-CSF and CpG to induce differentiation of AML blasts in vitro, a significant vaccine-like T cell response, and durable remission in syngeneic murine models of AML.
Intratumoral ATT-02 combines the ATTimmune scaffold coupled with Interleukin 12 (IL-12) to show potent anti-tumor immunity compared to IL-12 alone in multiple single tumor syngeneic models and abscopal syngeneic models. Complete responses were observed in two colon carcinoma models (localized and abscopal) after a single dose of ATT-02. Of interest, ATTimmune alone had anti-tumor activity with delayed tumor progression and in vitro, shows a repolarization of macrophages to an immunogenic phenotype capable of driving T cell activation with addition of IL-12 enhances this effect.
"We are excited to present our preclinical data for ATT-01 and ATT-02 at the AACR (Free AACR Whitepaper) Annual Meeting," said David Sherris, President and Chief Executive Officer of Attivare Therapeutics. "Here, we present ATTimmune, a novel silica-based platform to deliver potent immune agonists to combat cancer. ATTimmune has advantages over other drug delivery technologies as it can bind a variety of therapeutic agents with a high payload, be it biologics, small molecules, gene therapy or even cellular technologies to its surface without alteration of the therapeutic agents. ATTimmune controllably releases drug over time within a 21-day period. Due to size, ATTimmune remains at its injected location thereby keeping drug where activity is required, as in the tumor microenvironment. As such, ATTimmune has the capability of reducing or eliminating toxicity for drugs having systemic toxicity."
Details of the poster presentations at AACR (Free AACR Whitepaper) 2025 are as follows:
Title: Delivery of CpG and GM-CSF in a novel silica-based scaffold leads differentiation of AML blasts and T cell-dependent immunity in syngeneic AML tumor models
Abstract Presentation Number: 3467
Session Title: Local Treatments, Novel Tools, and Delivery Systems to Manipulate Tumor Immunity
Session Date and Time: Monday, April 28, from 2 p.m. to 5 p.m. CT (3 p.m. to 6 p.m. ET)
Location: Poster Section 37
Poster Board Number 6
Title: A single intratumoral injection of Il-12 bound to mesoporous silica rods generates effective anti-tumor immune responses and tumor growth control in multiple syngeneic tumor models
Abstract Presentation Number: 3476
Session Title: Local Treatments, Novel Tools, and Delivery Systems to Manipulate Tumor Immunity
Session Date and Time: Monday, April 28, from 2 p.m. to 5 p.m. CT (3 p.m. to 6 p.m. ET)
Location: Poster Section 37
Poster Board Number 15